Cat. No.: HY-N0083

Betulin

(Synonyms: Trochol)

15 Cited Publications

Customer Review

Based on 15 publication(s) in Google Scholar

Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC₅₀ of 14.5 μM in K562 cell line.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 473-98-3
Formula: C₃₀H₅₀O₂
Molecular Weight:442.72

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Betulin Chemical Structure

CAS No.: 473-98-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC₅₀ of 14.5 μM in K562 cell line^[1]^[2].

IC₅₀ & Target

IC50: 14.5 μM (SREBP, K562 cell), 74.1 μM (SREBP, HeLa cell), 17.1 μM (SREBP, GOTO cell)^[1], 21.09 μM (SREBP, 181P cell), 20.62 μM (SREBP, HeLa cell)^[2]

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	EC₅₀	28.8 μM Compound: Betulin	Cytotoxicity against human 518A2 cells by SRB assay Cytotoxicity against human 518A2 cells by SRB assay	[PMID: 26007303]
518A2	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 26547057]
518A2	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 27142753]
8505C	EC₅₀	>30 μM Compound: Betulin	Cytotoxicity against human 8505C cells by SRB assay Cytotoxicity against human 8505C cells by SRB assay	[PMID: 26007303]
A2780	IC₅₀	6.1 μM Compound: 10	Cytotoxicity against human A2780 cells after 4 days by MTT assay Cytotoxicity against human A2780 cells after 4 days by MTT assay	[PMID: 19702283]
A2780	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 24467317]
A2780	EC₅₀	29.3 μM Compound: Betulin	Cytotoxicity against human A2780 cells by SRB assay Cytotoxicity against human A2780 cells by SRB assay	[PMID: 26007303]
A2780	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 26547057]
A2780	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 27142753]
A2780	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A-375	IC₅₀	28 μM Compound: 1, BE, Betulin	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26280921]
A-375	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A549	IC₅₀	>316 μM Compound: 13	Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge	[PMID: 15730243]
A549	IC₅₀	>316 μM Compound: 13	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 15730243]
A549	IC₅₀	3.8 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 19115839]
A549	IC₅₀	>200 μM Compound: 2	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	IC₅₀	3.8 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	3.8 μM Compound: 2	Cytotoxicity against human A549 cells by resazurin reduction test Cytotoxicity against human A549 cells by resazurin reduction test	[PMID: 19285391]
A549	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 24467317]
A549	EC₅₀	20.6 μM Compound: Betulin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 26007303]
A549	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 26547057]
A549	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 27142753]
A549	IC₅₀	18.15 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
A549	IC₅₀	59.73 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay	[PMID: 31158746]
ADR5000 cell line	IC₅₀	56.5 μM Compound: betulin	Cytotoxicity against human CEM/ADR5000 by XTT assay Cytotoxicity against human CEM/ADR5000 by XTT assay	[PMID: 20527917]
B16	ED₅₀	4.8 μM Compound: 4	Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days	[PMID: 12027734]
B16	IC₅₀	27.4 μM Compound: 4	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
Bcap37	IC₅₀	25.5 μM Compound: 1, BE, Betulin	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 26280921]
Bel-7402	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 24467317]
BGC-823	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 24467317]
BGC-823	IC₅₀	>20 μM Compound: Betulin	Antiproliferative activity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31708185]
BV-2	IC₅₀	>10 μM Compound: 23	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 24467317]
BXPC-3	GI₅₀	9.3 μg/mL Compound: 1	Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay	[PMID: 24694263]
BXPC-3	GI₅₀	9.3 μg/mL Compound: Betulin	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 29303263]
CAPAN-1	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
CCRF-CEM	IC₅₀	>250 μM Compound: 1 (Betulinine)	Concentration required to kill 50 % of human T-lymphoblastic leukemia cell line (CEM) Concentration required to kill 50 % of human T-lymphoblastic leukemia cell line (CEM)	[PMID: 16051489]
CCRF-CEM	IC₅₀	>250 μM/L Compound: 1 (Betulinine)	Concentration required to kill 50 % of human T-lymphoblastic leukemia cell line (CEM) Concentration required to kill 50 % of human T-lymphoblastic leukemia cell line (CEM)	[PMID: 16051489]
CCRF-CEM	IC₅₀	250 μM Compound: 2	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 17371067]
CCRF-CEM	IC₅₀	50.8 μM Compound: betulin	Cytotoxicity against human CCRF-CEM by XTT assay Cytotoxicity against human CCRF-CEM by XTT assay	[PMID: 20527917]
CCRF-CEM	IC₅₀	250 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 22551630]
CCRF-CEM	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay	[PMID: 27236068]
CHO	EC₅₀	>10 μM Compound: Betulin	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	0 μM Compound: Betulin	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DLD-1	IC₅₀	6.6 μM Compound: 1	Cytotoxicity against human DLD1 cells after 48 hrs Cytotoxicity against human DLD1 cells after 48 hrs	[PMID: 19115839]
DLD-1	IC₅₀	>200 μM Compound: 2	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
DLD-1	IC₅₀	6.6 μM Compound: 2	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	6.6 μM Compound: 2	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 19285391]
DU-145	GI₅₀	>10 μg/mL Compound: 1	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 24694263]
DU-145	CC₅₀	161.8 μM Compound: 11	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	136.7 μM Compound: 11	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	GI₅₀	>10 μg/mL Compound: Betulin	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 29303263]
ECa-109 cell line	IC₅₀	26.64 μM Compound: 1	Cytotoxicity against human ECA109 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human ECA109 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
Epithelial cell	IC₅₀	>20 μM Compound: betulin	Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay	[PMID: 18826277]
FaDu	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
Fibroblast	CC₅₀	7.6 μM Compound: 1	Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay	[PMID: 33877845]
H9	EC₅₀	23 μM Compound: 4	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8176401]
H9	IC₅₀	45 μM Compound: 4	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8176401]
H9	EC₅₀	23 μM Compound: 6	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.	[PMID: 9804704]
H9	IC₅₀	43.7 μM Compound: 6	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.	[PMID: 9804704]
H9	EC₅₀	23 μM Compound: 3	Compound was evaluated for anti-HIV activity in H9 lymphocytes Compound was evaluated for anti-HIV activity in H9 lymphocytes	[PMID: 9871747]
H9	IC₅₀	43.7 μM Compound: 3	Compound was evaluated for cytotoxicity in H9 lymphocytes Compound was evaluated for cytotoxicity in H9 lymphocytes	[PMID: 9871747]
H9	EC₅₀	23 μM Compound: 23, BN	Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication	10.1007/s00044-010-9467-2
HCT-116	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
HCT-8	IC₅₀	>10 μM Compound: 23	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 24467317]
HEK293	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	>10 μg/mL Compound: betulin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 16038541]
HeLa	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human HeLa cells after 96 hrs by SRB assay Cytotoxicity against human HeLa cells after 96 hrs by SRB assay	[PMID: 27142753]
HeLa	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	12.2 μM Compound: Betulin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31708185]
HEp-2	IC₅₀	>10 μg/mL Compound: betulin	Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay	[PMID: 16038541]
HEp-2	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HepG2	IC₅₀	17 μM Compound: 13	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	10.7 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
HepG2	IC₅₀	>20 μM Compound: Betulin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31708185]
HL-60	IC₅₀	30.94 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
HL-60	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
HT-29	IC₅₀	>250 μM Compound: 1 (Betulinine)	Concentration required to kill 50 % of human colon cancer cell line HT-29 Concentration required to kill 50 % of human colon cancer cell line HT-29	[PMID: 16051489]
HT-29	IC₅₀	>250 μM/L Compound: 1 (Betulinine)	Concentration required to kill 50 % of human colon cancer cell line HT-29 Concentration required to kill 50 % of human colon cancer cell line HT-29	[PMID: 16051489]
HT-29	EC₅₀	>30 μM Compound: Betulin	Cytotoxicity against human HT-29 cells by SRB assay Cytotoxicity against human HT-29 cells by SRB assay	[PMID: 26007303]
HT-29	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 27142753]
HT-29	IC₅₀	>10 μM Compound: 12	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HT-29	IC₅₀	>10 μM Compound: 12	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	IC₅₀	>20 μM Compound: Betulin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31708185]
HT-29	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
HUVEC	ED₅₀	>5 μg/mL Compound: betulin	Cytotoxicity against human HUVEC Cytotoxicity against human HUVEC	[PMID: 15270571]
J774	IC₅₀	67.1 μM Compound: 6	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
K562	IC₅₀	>250 μM Compound: 1 (Betulinine)	Concentration required to kill 50 % of human paclitaxel-resistant subline of K562 cells (K-562-Tax) Concentration required to kill 50 % of human paclitaxel-resistant subline of K562 cells (K-562-Tax)	[PMID: 16051489]
K562	IC₅₀	>250 μM Compound: 1 (Betulinine)	Concentration required to kill 50 % of human chronic myelogenous leukemia cell line K562 Concentration required to kill 50 % of human chronic myelogenous leukemia cell line K562	[PMID: 16051489]
K562	IC₅₀	>250 μM/L Compound: 1 (Betulinine)	Concentration required to kill 50 % of human chronic myelogenous leukemia cell line K562 Concentration required to kill 50 % of human chronic myelogenous leukemia cell line K562	[PMID: 16051489]
K562	IC₅₀	12.89 μM Compound: 1	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
K562	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
KB	IC₅₀	>10 μg/mL Compound: betulin	Cytotoxicity against vincristine-sensitive human KB cells after 72 hrs by alamar blue assay Cytotoxicity against vincristine-sensitive human KB cells after 72 hrs by alamar blue assay	[PMID: 15043435]
KB	ED₅₀	>5 μg/mL Compound: betulin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15270571]
KB	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	ED₅₀	>20 μg/mL Compound: 2	Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line. Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.	[PMID: 9873420]
KM-20L2	GI₅₀	>10 μg/mL Compound: 1	Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay	[PMID: 24694263]
KM-20L2	GI₅₀	>10 μg/mL Compound: Betulin	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay	[PMID: 29303263]
L02	IC₅₀	26.82 μM Compound: 1	Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28671831]
LN-229	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
LNCaP	ED₅₀	>5 μg/mL Compound: betulin	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15270571]
Lu1	ED₅₀	>5 μg/mL Compound: betulin	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15270571]
MCF7	IC₅₀	23.3 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 19115839]
MCF7	GI₅₀	>10 μg/mL Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24694263]
MCF7	EC₅₀	24.4 μM Compound: Betulin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 26007303]
MCF7	IC₅₀	19.3 μM Compound: 1, BE, Betulin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26280921]
MCF7	EC₅₀	>30 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 26547057]
MCF7	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 27142753]
MCF7	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	GI₅₀	>10 μg/mL Compound: Betulin	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 29303263]
MCF7	IC₅₀	43.88 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay	[PMID: 31158746]
MCF7	EC₅₀	>30 μM Compound: BN	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
MDA-MB-231	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	>10 μM Compound: 12	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-231	IC₅₀	96.19 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay	[PMID: 31158746]
MDA-MB-231	IC₅₀	24.57 μM Compound: 6	Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay	[PMID: 33359608]
MDA-MB-435	IC₅₀	>10 μM Compound: 12	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDCK	IC₅₀	>20 μM Compound: Betulin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31708185]
MGC-803	IC₅₀	30.2 μM Compound: 1, BE, Betulin	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 26280921]
MIA PaCa-2	IC₅₀	95 μM Compound: 6	Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay	[PMID: 33359608]
NCI-H460	GI₅₀	7.4 μg/mL Compound: 1	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 24694263]
NCI-H460	GI₅₀	7.4 μg/mL Compound: Betulin	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 29303263]
NCI-H460	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
NIH3T3	EC₅₀	>30 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 26547057]
NIH3T3	EC₅₀	>30 μM Compound: BN	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
OVCAR-3	IC₅₀	>10 μM Compound: 12	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
PC-3	IC₅₀	>250 μM Compound: 1 (Betulinine)	Concentration required to kill 50 % of human prostate cancer PC3 cells Concentration required to kill 50 % of human prostate cancer PC3 cells	[PMID: 16051489]
PC-3	IC₅₀	>250 μM/L Compound: 1 (Betulinine)	Concentration required to kill 50 % of human prostate cancer PC3 cells Concentration required to kill 50 % of human prostate cancer PC3 cells	[PMID: 16051489]
PC-3	IC₅₀	17.9 μM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs Cytotoxicity against human PC3 cells after 48 hrs	[PMID: 19115839]
PC-3	IC₅₀	22.4 μM Compound: 1, BE, Betulin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26280921]
SF-268	GI₅₀	>10 μg/mL Compound: 1	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 24694263]
SF-268	GI₅₀	>10 μg/mL Compound: Betulin	Growth inhibition of human SF268 cells after 48 hrs by SRB assay Growth inhibition of human SF268 cells after 48 hrs by SRB assay	[PMID: 29303263]
SiHa	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SK-MEL-2	IC₅₀	>250 μM Compound: 1 (Betulinine)	Concentration required to kill 50 % of human melanoma SK-MEL2 cells Concentration required to kill 50 % of human melanoma SK-MEL2 cells	[PMID: 16051489]
SK-MEL-2	ED₅₀	>20 μg/mL Compound: 2	Cytotoxicity against cultured human melanoma (MEL-2) cell line. Cytotoxicity against cultured human melanoma (MEL-2) cell line.	[PMID: 9873420]
T47D	IC₅₀	20.72 μM Compound: 1	Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay	[PMID: 31158746]
Vero	IC₅₀	>10 μg/mL Compound: betulin	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 16038541]
Vero	CC₅₀	165 μM Compound: Betulin	Cytotoxicity against African green monkey Vero cells after 2 days by neutral red uptake assay Cytotoxicity against African green monkey Vero cells after 2 days by neutral red uptake assay	[PMID: 26112446]
Vero	IC₅₀	0.9 μM Compound: Betulin	Antiviral activity against HSV-1 F infected in African green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against HSV-1 F infected in African green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 26112446]
Vero	IC₅₀	9.4 μM Compound: Betulin	Antiviral activity against HSV-2 G infected in African green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against HSV-2 G infected in African green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 26112446]
Vero	CC₅₀	>500 μM Compound: 11	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	>500 μM Compound: 11	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
WI-38	IC₅₀	1.4 μM Compound: 13	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	20.3 μM Compound: 13	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
Z-138	IC₅₀	>100 μM Compound: BE	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]

In Vitro

Betulin displays a broad spectrum of biological and pharmacological properties, among which the anticancer and chemopreventive activity attract most of the attention. Betulin has been shown to elicit anticancer properties by inhibiting cancer cells growth. Betulin has exhibited quite a different range of its antiproliferative activity, depending on cancer cells type, from a weak inhibition of cell proliferation in human erythroleukaemia cell line (K562) to a strong inhibition in human neuroblastoma cells (SK-N-AS), where the effect has been most pronounced. Additionally, Betulin has also been found to express significant cytotoxicity against primary cancer cells cultures isolated from tumour samples obtained from ovarian, cervical carcinoma, and glioblastoma patients, where the IC₅₀ values have ranged from 2.8 to 3.4 μM, being significantly lower, when compared with established cell lines^[1].
The cytotoxic activity of crude birch bark extract and purified Betulin and betulinic acid towards human gastric carcinoma (EPG85-257) and human pancreatic carcinoma (EPP85-181) drug-sensitive and drug-resistant (daunorubicin and mitoxantrone) cell lines are compared. Significant differences in sensitivity between cell lines depending on the compound used are shown, suggesting that both Betulin and Betulinic acid can be considered as a promising leads in the treatment of cancer^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Betulin could improve glucose intolerance and modify basal learning performance. Treatment with Betulin significantly restores SOD activity and decreased MDA content in hippocampus. Betulin also markedly reduces the contents of inflammatory cytokines in serum and hippocampus. Furthermore, administration of Betulin effectively upregulated the expressions of Nrf2, HO-1 and blocked the phosphorylations of IκB, NF-κB. In summary, Betulin might exhibit protective effect on cognitive decline in STZ-induced diabetic rats through HO-1/Nrf-2/ NF-κB pathway^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 473-98-3
Appearance Solid
Molecular Weight 442.72
Formula C₃₀H₅₀O₂
Color White to off-white
SMILES

C=C(C)[C@@H]1CC[C@]2(CO)CC[C@@]3(C)[C@]4(C)CC[C@@]5([H])C(C)(C)[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3([H])[C@]21[H]
Synonyms

Trochol
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (15)

All 2D/3D Cell Culture and DifferentiationWB

Sort by:

Journal Impact Factor

Cancer Cell

Midkine as a driver of age-related changes and increase in mammary tumorigenesis. [Abstract]

2024 Sep 26:S1535-6108(24)00350-7. PMID: 39366375

Betulin purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Sep 26:S1535-6108(24)00350-7. [Abstract]

Representative images of rat mammary organoids treated with midkine (300 ng/mL), betulin (5 μM), fatostatin (5 μM) and rapamycin (25 nM) for 5 days.

Betulin purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Sep 26:S1535-6108(24)00350-7. [Abstract]

Immunoblot showing the expression of MDK, mature SREBF1 (SREBF1 (M)), S6, p-S6(Ser235/236), AKT, p-AKT(Ser473) in the organoids treated with Midkine (300 ng/mL), betulin (5 μM), fatostatin (5 μM) and rapamycin (25 nM) for 5 days. Tubulin serves as loading control.
Nat Commun

Cholesterol sulfate alleviates ulcerative colitis by promoting cholesterol biosynthesis in colonic epithelial cells. [Abstract]

2022 Jul 30;13(1):4428. PMID: 35908039
Autophagy

Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway. [Abstract]

2021 Jul;17(7):1592-1613. PMID: 32432943
Redox Biol

Accumulated cholesterol protects tumours from elevated lipid peroxidation in the microenvironment. [Abstract]

2023 Jun:62:102678. PMID: 36940607
Cell Death Dis

Combined metformin and simvastatin therapy inhibits SREBP2 maturation and alters energy metabolism in glioma. [Abstract]

2024 Nov 9;15(11):809. PMID: 39521788
Cell Death Dis

SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. [Abstract]

2019 Sep 11;10(9):672. PMID: 31511501
Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
Apoptosis

SREBP2 confers ferroptosis resistance by targeting GPX4 in colorectal cancer. [Abstract]

2026 Jan 10;31(1):30. PMID: 41518439
Cell Rep

Scap stabilizes PKM2 to promote glycolysis and enhance anti-fungal immunity in macrophages. [Abstract]

2026 Mar 13;45(3):117106. PMID: 41831231
Mol Metab

CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing. [Abstract]

2022 Mar:57:101428. PMID: 34974159
Phytother Res

Betulin Protects Against Cardiac Hypertrophy by Improving AMPK/Nrf2-Dependent Mitochondrial Function. [Abstract]

2026 May;40(5):2878-2894. PMID: 41804091
J Invest Dermatol

LCN2 Mediates Skin Inflammation in Psoriasis through the SREBP2‒NLRC4 Axis. [Abstract]

2022 Aug;142(8):2194-2204.e11. PMID: 35120997
J Nutr Biochem

F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish. [Abstract]

2023 Dec:122:109452. PMID: 37748621
FASEB J

SREBP-1-mediated lipogenesis confers resistance to ferroptosis and improves endothelial injury. [Abstract]

2024 Jul 15;38(13):e23806. PMID: 38970404
Front Oncol

Overexpression of ABCC1 Confers Drug Resistance to Betulin. [Abstract]

2021 Feb 25;11:640656. PMID: 33718236

Solvent & Solubility

In Vitro:

DMSO : 3.33 mg/mL (7.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2588 mL

11.2938 mL

22.5876 mL

5 mM

0.4518 mL

2.2588 mL

4.5175 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 0.2 mg/mL (0.45 mM); Clear solution

Protocol 2

Add each solvent one by one: 5% DMSO 95% Corn Oil

Solubility: ≥ 0.2 mg/mL (0.45 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 3 mg/mL (6.78 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Chemoresistance is tested using a proliferation assay based on sulphorhodamine B staining. Briefly, 800 cells per well are seeded in triplicate in 96-well plates. After attachment for 24 h, substances are added in dilution series for a 5-day incubation, before SRB staining is performed. Incubation is terminated by replacing the medium with 10% trichloroacetic acid, followed by further incubation at 4°C for 1h. Subsequently, the plates are ished five times with water and stained by adding 100 μL 0.4% SRB in 1% acetic acid for 10 min at room temperature. Ishing the plates five times with 1% acetic acid eliminated unbound dye. After air-drying and re-solubization of the protein bound dye in 10 mM Tris-HCl (pH=8.0), absorbance is read at 562 nm^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Rats: The rats are randomLy divided into five groups (n=10): control group, STZ group, STZ+betulin (20 mg/kg) group, STZ+betulin (40 mg/kg) group. Diabetes is induced by STZ (30 mg/kg, i.p.) dissolved in citrate buffer (pH 4.4, 0.1 M) using 1 mL syringe for 4 weeks, meanwhile the control rats receive an equal volume of citrate buffer. Thereafter, the diabetic rats are treated with betulin (20 mg/kg, 40 mg/kg) for another 4 weeks^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Król SK, et al. Comprehensive review on betulin as a potent anticancer agent. Biomed Res Int. 2015;2015:584189. [Content Brief]

[2]. Drag M, et al. Comparision of the Cytotoxic Effects of Birch Bark Extract, Betulin and Betulinic Acid Towards Human Gastric Carcinoma and Pancreatic Carcinoma Drug-sensitive and Drug-Resistant Cell Lines. Molecules. 2009 Apr 24;14(4):1639-51. [Content Brief]

[3]. Ma C, et al. Protective effect of betulin on cognitive decline in streptozotocin (STZ)-induced diabetic rats. Neurotoxicology. 2016 Dec;57:104-111. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2588 mL	11.2938 mL	22.5876 mL	56.4691 mL
DMSO	5 mM	0.4518 mL	2.2588 mL	4.5175 mL	11.2938 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Betulin

Apoptosis Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-diabetic Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Betulin

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (15)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Betulin Related Classifications

Cat. No.: HY-N0083